Business Wire

NY-XYLEM

20.1.2022 16:32:04 CET | Business Wire | Press release

Share
Xylem Clocks 113,000 Volunteer Hours in 2021, Doubling Time Donated to Help Tackle Water Challenges in 55 Countries

Global water technology company, Xylem (NYSE:XYL), announced today that almost 80 percent of its 16,000 employees volunteered their time to help solve urgent water challenges in 2021. Xylem’s global team collectively donated 113,000 hours in their communities, across 55 countries.

The commitment of volunteer hours doubled from 2020 to 2021, despite the challenges of COVID-19. Xylem employees stepped up both in person, in their own communities, and virtually, finding new ways to make a difference. Initiatives included cleaning up waterways, supporting disaster response teams, and providing water education.

"Volunteering is one way we invest in our mission to solve the world’s biggest water challenges,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem. “Our colleagues, customers and NGO partners showed real passion, last year – doubling the number of hours they volunteered, compared with 2020. It was particularly encouraging to see this uplift in the face of COVID-19. They found so many creative ways to help communities become more resilient – mentoring young people online, championing the efforts of our NGO partners, and supporting humanitarian relief efforts. It’s just so inspiring to see the impact they’ve had.”

Xylem’s volunteering initiatives are part of its corporate social responsibility program, Xylem Watermark. Xylem provides 10 hours of time off annually for employees to volunteer, with some of the volunteers’ efforts also contributing to Xylem’s 2025 Sustainability Goals , which include: providing access to clean water and sanitation for at least 20 million people living at the base of the global economic pyramid; providing water and WASH (Water and Sanitation Hygiene) education for 15 million people; and giving 1% company profits to water-related causes and education around the world.

In 2021, Xylem Watermark volunteering included:

  • Xylem China’s team supported communities in Henan and Shanxi Province affected by record-breaking floods, which affected millions of people and left many without access to safe or clean drinking water. The team set up a 24-hour contact center to support affected customers and assisted in the donation of pumps across the province to help discharge floodwater. In addition, Xylem’s China team donated food and water to the affected communities.
  • Xylem employees joined relief efforts in western Germany last summer, when almost a quarter of people living on the River Ahr experienced severe flooding, and more than 3,000 homes and businesses were destroyed. Xylem employees took part in clean-up efforts, raised funds to support the evacuation of affected families, and distributed food and hygiene kits to emergency shelters.
  • Over 800 Xylem employees, customers and community members participated in “Aquaton,” a month-long mileage challenge which raised funds for clean water access projects spanning seven countries in Latin America.
  • A diverse team of colleagues from South Africa, Europe and North America donated their engineering skills to support the work of Engineers Without Borders, rehabilitating WASH facilities at rural health clinics in Malawi.

About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our more than 16,000 diverse employees delivered revenue of $4.88 billion in 2020. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com .

About Xylem Watermark
Xylem Watermark, the Company’s corporate citizenship program, was initiated in 2008, with a focus on protecting and providing safe water resources around the world and also educating people on water-related issues. The global initiative, which encompasses employee and stakeholder engagement, provides access to clean drinking water and sanitation, and humanitarian emergency response to help communities become more water-secure and sustainable.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye